| Name | Title | Contact Details |
|---|
HealthLinx Executive Search is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UAB Huntsville Regional Medical Campus is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers. The company’s streamlined management structure allows it to respond more quickly to changes in the marketplace and provide a higher level of service that is customized for each consumer. Moreover, BioRx helps to provide a more cost-effective level of healthcare – in particular by moving patients from costly facility-based infusion sites to their homes, thereby allowing us to closely monitor the administration and outcomes of complex infusion therapies. BioRx consumer services include home delivery of specialty intravenous and injectable pharmaceuticals, medical supplies, nursing support, reimbursement coordination, consumer advocacy, and highly customized care plans. The company also provides professional consulting services to business partners within the insurance and pharmaceutical manufacturing industries.
Global Village Consulting Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.